Genetic determinants excluding GBCR::ABL mutations of imatinib mesylate therapy response among chronic myeloid leukaemia patients in Malaysia
Despite imatinib mesylate (IM) being the frontline drug for successful treatment of chronic myeloid leukaemia (CML), a significant proportion of CML patients on IM therapy develop resistance and attain poor outcome. The objective of the present study was to investigate the contribution of selecte...
Saved in:
Main Author: | Ismail, Siti Mariam |
---|---|
Format: | Thesis |
Language: | English |
Published: |
2023
|
Subjects: | |
Online Access: | http://eprints.usm.my/58908/1/SITI%20MARIAM%20ISMAIL%20-FINAL%20THESIS%20S-UD000420%28R%29%2024%20pages.pdf |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The local experience of imatinib mesylate in the treatment of chronic myeloid leukaemia /
by: Bee, Ping Chong
Published: (2005) -
Detection of PDGFRA mutations at exons 12 and 18 among chronic myeloid leukemia patients treated with imatinib mesylate
by: Razali, Ruzi Hamimi
Published: (2015) -
Influence of tert gene expression, telomerase activity and telomere length in relation to imatinib mesylate resistance in Malaysian chronic myeloid leukaemia patients
by: Shamshudin, Wati @ Hayati Mohd
Published: (2020) -
Application of high resolution melting (HRM) analysis in detection of PDGFRA gene mutations among chronic myeloid leukemia patients treated with imanitib mesylate
by: Rashid, Nur Sabrina Abd
Published: (2020) -
Influence of ORM1, PXR, CAR, CYP3A4 and CYP3A5 gene polymorphisms in mediating susceptibility risk to chronic myeloid leukaemia and response to imatinib mesylate therapy
by: Maddin, Najlaa
Published: (2017)